FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change
Movement Disorders · 2024-06 · 39 (6) · 965-974
DOI: 10.1002/mds.29788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 20.03.2024. Verfasst von Andreas Traschütz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Division "Translational Genomics of Neurodegenerative Diseases," Hertie-Institute for Clinical Brain Research and Center of Neurology, Unive…. Hauptthemen laut MEDLINE: Activities of Daily Living. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung TreatHSP network, Else Kröner-Fresenius-Stiftung, Medizinische Fakultät, Eberhard Karls Universität Tübingen.
Abstract (Originalsprache)
Background
Patient‐focused outcomes present a central need for trial‐readiness across all ataxias. The Activities of Daily Living part of the Friedreich Ataxia Rating Scale (FARS‐ADL) captures functional impairment and longitudinal change but is only validated in Friedreich Ataxia.
Objective
Validation of FARS‐ADL regarding disease severity and patient‐meaningful impairment, and its sensitivity to change across genetic ataxias.
Methods
Real‐world registry data of FARS‐ADL in 298 ataxia patients across genotypes were analyzed, including (1) cross‐correlation with FARS‐stage, Scale for the Assessment and Rating of Ataxia (SARA), Patient‐Reported Outcome Measure (PROM)‐ataxia, and European Quality of Life 5 Dimensions visual analogue scale (EQ5D‐VAS); (2) sensitivity to change within a trial‐relevant 1‐year median follow‐up, anchored in Patient Global Impression of Change (PGI‐C); and (3) general linear modeling of factors age, sex, and depression (nine‐item Patient Health Questionnaire [PHQ‐9]).
Results
FARS‐ADL correlated with overall disability (rho FARS‐stage = 0.79), clinical disease severity (rho SARA = 0.80), and patient‐reported impairment (rho PROM‐ataxia = 0.69, rho EQ5D‐VAS = –0.37), indicating comprehensive construct validity. Also at item level, and validated within genotype (SCA3, RFC1), FARS‐ADL correlated with the corresponding SARA effector domains; and all items correlated to EQ5D‐VAS quality of life. FARS‐ADL was sensitive to change at a 1‐year interval, progressing only in patients with worsening PGI‐C. Minimal important change was 1.1. points based on intraindividual variability in patients with stable PGI‐C. Depression was captured using FARS‐ADL (+0.3 points/PHQ‐9 count) and EQ5D‐VAS, but not FARS‐stage or SARA.
Conclusion
FARS‐ADL reflects both disease severity and patient‐meaningful impairment across genetic ataxias, with sensitivity to change in trial‐relevant timescales in patients perceiving change. It thus presents a promising patient‐focused outcome for upcoming ataxia trials. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Division "Translational Genomics of Neurodegenerative Diseases," Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
- Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
- Department of Neurology, University Hospital Bonn, Bonn, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
- Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Andreas Traschütz, Holger Hengel, Thomas Klockgether, José Luiz Pedroso, Matthis Synofzik
Förderung
- Bundesministerium für Bildung und Forschung TreatHSP network
- Else Kröner-Fresenius-Stiftung
- Medizinische Fakultät, Eberhard Karls Universität Tübingen
- Ministero della Salute
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Medizinischen Fakultät, Eberhard Karls Universität Tübingen
Zitieren
APA
Traschütz, A., Fleszar, Z., Hengel, H., Klockgether, T., Erdlenbruch, F., Falkenburger, B. H., Klopstock, T., Öztop-Çakmak, Ö., Pedroso, J. L., Santorelli, F. M., Schöls, L., RFC1 Study Group, PREPARE Consortium, & Synofzik, M. (2024). FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change. Movement Disorders, 39(6), 965-974. https://doi.org/10.1002/mds.29788
Vancouver
Traschütz A, Fleszar Z, Hengel H, Klockgether T, Erdlenbruch F, Falkenburger BH, et al. FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change. Movement Disorders. 2024;39(6):965-974. doi:10.1002/mds.29788
BibTeX
@article{Traschtz2024,
author = {Traschütz, Andreas and Fleszar, Zofia and Hengel, Holger and Klockgether, Thomas and Erdlenbruch, Friedrich and Falkenburger, Björn H and Klopstock, Thomas and Öztop-Çakmak, Özgür and Pedroso, José Luiz and Santorelli, Filippo M and Schöls, Ludger and RFC1 Study Group, PREPARE Consortium, RFC1 Study Group, PREPARE Consortium and Synofzik, Matthis},
title = {FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {6},
pages = {965--974},
doi = {10.1002/mds.29788}
}
EUVIMED